147 related articles for article (PubMed ID: 34648951)
21. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
22. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
23. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer.
Levink IJM; Visser IJ; Koopmann BDM; van Driel LMJW; Poley JW; Cahen DL; Bruno MJ; Fuhler GM
Gastrointest Endosc; 2022 Nov; 96(5):801-813.e2. PubMed ID: 35537661
[TBL] [Abstract][Full Text] [Related]
24. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
[TBL] [Abstract][Full Text] [Related]
25. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
[TBL] [Abstract][Full Text] [Related]
26. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
27. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
28. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
29. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
30. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
31. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
32. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
33. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
Ando Y; Dbouk M; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Dbouk A; Blackford AL; Lin MT; Lennon AM; Burkhart RA; He J; Sokoll L; Eshleman JR; Canto MI; Goggins M
J Clin Oncol; 2024 Mar; ():JCO2301573. PubMed ID: 38457748
[TBL] [Abstract][Full Text] [Related]
34. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study.
Brand RE; Persson J; Bratlie SO; Chung DC; Katona BW; Carrato A; Castillo M; Earl J; Kokkola A; Lucas AL; Moser AJ; DeCicco C; Mellby LD; King TC
Clin Transl Gastroenterol; 2022 Feb; 13(3):e00468. PubMed ID: 35166713
[TBL] [Abstract][Full Text] [Related]
35. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
36. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
37. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
38. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
40. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
